Biomarkers and uses thereof for treatment of cancer with cd19-targeted adoptive cell therapies
AssigneesMemorial Sloan Kettering Cancer Center, Sloan-Kettering Institute for Cancer Research, Memorial Hospital for Cancer and Allied Diseases, Takeda Pharmaceutical Company Limited
InventorsMichel SADELAIN, Jae H. PARK, Varsha SUNDARESAN, Reshma SINGH
Life of this patent
Estimating the term…
Abstract
The presently disclosed subject matter provides methods for identifying subjects that are responsive or non-responsive to certain adoptive cell therapies or compositions comprising the same. In addition, methods for identifying subjects that have an increased likelihood or a reduced likelihood to response to certain adoptive cell therapies or compositions comprising the same are also provided. Moreover, the presently disclosed subject matter provides cells and compositions comprising a CD19-targeted chimeric receptor.
Claims35
A method comprising:
- (a) measuring an expression level of at least one of CD57, TIM3, KLRG1, CTLA4, LAG3 and PD1 in an immunoresponsive cell of a subject;
- (b) comparing the expression level to a reference sample;
- and
- (c) identifying the subject as (i) responsive or as having an increased likelihood to respond to an adoptive cell therapy, or (ii) non-responsive or as having a reduced likelihood to respond to an adoptive cell therapy.
A composition comprising a cell comprising a CD19-targeted chimeric receptor, wherein the CD19-targeted chimeric receptor comprises an extracellular antigen-binding domain, a transmembrane domain, and an intracellular domain, wherein the extracellular antigen-binding domain comprises a heavy chain variable region (VH) comprising a CDR1 comprising the amino acid sequence set forth in SEQ ID NO:
- 10, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO:
- 11, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO:
- 12, and a light chain variable region (VL) comprising a CDR1 comprising the amino acid sequence set forth in SEQ ID NO:
- 13, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO:
- 14, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO:
- 15.
Dependencies are inferred from the claim text.